Your session is about to expire
← Back to Search
BBBD + Carboplatin for Glioblastoma
Study Summary
This trial is testing whether a device that opens the blood-brain-barrier is safe and feasible for treating recurrent glioblastoma with carboplatin monotherapy.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2008 Phase 2 trial • 149 Patients • NCT02004093Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My diagnosis is glioblastoma confirmed by tissue analysis.I am not pregnant or breastfeeding.I am not pregnant and use effective birth control methods.I am between 18 and 80 years old.I have recovered from major side effects of my previous treatments.My cancer has worsened after the first treatment.My cancer is located in my cerebellum, spinal cord, or brain stem.I have had a recent bleeding in my brain.You have metal objects implanted in your head or brain.You have a known sensitivity or medical reasons that prevent you from using ultrasound contrast agent or perflutren.I have very high blood pressure.I have an active Hepatitis B, Hepatitis C, or HIV infection.You have severe depression that is not well managed with treatment.You are allergic or have a bad reaction to gadolinium-based contrast agents.I have another cancer that is getting worse or needs treatment.I am scheduled for treatment with Carboplatin alone.You have a specific type of heart condition where blood flows abnormally between the right and left sides of your heart.I have a history of bleeding disorders or my tumor has bled on its own.I am currently on antibiotics for a cranial or systemic infection.I cannot lie on my back or have severe claustrophobia that medication can't help.I can speak and communicate verbally.My kidneys do not work well.You currently have a problem with using drugs or alcohol.I have heart disease or unstable blood pressure and heart rate.I have experienced side effects from carboplatin chemotherapy.
- Group 1: Exablate BBBD with carboplatin
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What is the cap for enrollees in this clinical trial?
"Affirmative, the information accessible on clinicaltrials.gov indicates that this health trial is currently recruiting participants. It was initially published in October 2020 and most recently modified in December 2021; it requires 50 individuals to be recruited at one medical centre."
Are researchers seeking out new participants for this experiment?
"Affirmative. Clinicaltrials.gov data reveals that this study, which was first made available on October 13th 2020, is looking for participants to enrol in the trial. The research necessitates 50 individuals at a single medical centre."
How can I become involved in this scientific investigation?
"This clinical trial is seeking 50 individuals aged between 18 and 80 who have glioblastoma. Other essential requirements for all applicants include verbal communicative ability, recovery from prior treatment's toxic side effects (at grade 0 or 1), and having an age within the specified range."
Are minors being considered for enrolment in this experiment?
"The eligibility criteria for this study necessitates that all participants should be below 80 years of age and over the age of majority."
What ailments has Exablate BBBD been found to be effective in treating?
"Exablate BBBD is a popularly employed treatment for lymphoma and non-hodgkin, as well as more advanced sarcomas. This therapeutic intervention can also be utilized to treat hodgkin disease in its infancy."
Share this study with friends
Copy Link
Messenger